The Vita Coco Company Inc vs McKesson Corporation — how do they compare? The Vita Coco Company Inc trades at $74.45 (market cap $4.23B), while McKesson Corporation trades at $801.98 (market cap $94.06B). The key difference: McKesson Corporation is far larger — about 22.2× The Vita Coco Company Inc's market cap, and McKesson Corporation pays a 0.41% dividend while The Vita Coco Company Inc pays none. Which is the better fit depends on your goals.
| COCO | MCK | |
|---|---|---|
Market Cap | $4.23B | $94.06B |
Sector | Technology | Health |
52-Week High | $84.02 | $995.69 |
52-Week Low | $32.30 | $659.01 |
Enterprise Value | $4.04B | $98.70B |
Dividend Yield | — | 0.41% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
McKesson (MCK) trades at $812.28, up 0.78% with a bullish technical signal. The stock shows consistent earnings beats, with Q1 2026 EPS of $11.69 exceeding expectations. Revenue grew to $359.05B in 2025, though net margins remain thin at 1.18%. Analysts maintain strong buy consensus (80%) with a $932.83 price target. Recent news highlights growth in specialty pharma and oncology services, supporting positive momentum.
Outlook remains positive driven by earnings strength and sector tailwinds, but risks include policy changes and high liabilities. The stock offers value with a P/E of 21.16 and P/S of 0.25, though investors should monitor debt levels and execution risks amid competitive pressures.
Trailing returns across standard periods
Latest headlines on both assets
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →